Opyl Limited announced that it has engaged leading global clinical trial expert and eminent business leader in the health technology sector, Dr. Hugo Stephenson, as an advisor to the board. His appointment is an important development in the Company's strategic review, which focuses on accelerating the growth of Opin and monetising the TrialKey technology platform. Dr. Stephenson is a medical doctor, technologist, biotech services entrepreneur and founder of a number of successful businesses in the international clinical trials industry, including: DrugDev, a leading provider of e-clinical technologies and clinical trial payment services; MediGuard, the largest online medication monitoring service; Health Research Solutions (HRS), a late phase contract research organisation; and MedSeed, a pioneer of hospital and GP decision support software.

Dr. Stephenson worked for many years as the founder of Quintiles' global late phase research division (now IQVIA) following the acquisition of HRS, and has considerable experience managing organizations within both a public market and private equity-backed environment. He is also the founder and past Chief Executive Officer of the Induction Healthcare Group PLC.